Bio-Techne Corp (TECH): Shareholders' Equity
$2.11B
As of 2026-06-30
+2.3%
3-year compound annual growth
+6.2%
5-year compound annual growth
+9.1%
10-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $2.11B | +9.9% | 2026-08-24, Balance as of period end |
| 2025-06-30 | $1.92B | -7.3% | 2026-08-24, Balance as of period end |
| 2024-06-30 | $2.07B | +5.2% | 2026-08-24, Balance as of period end |
| 2023-06-30 | $1.97B | +15.6% | 2024-08-22, Balance as of period end |
| 2022-06-30 | $1.70B | +8.9% | 2023-08-23, Balance as of period end |
| 2021-06-30 | $1.56B | +13.2% | 2022-08-24, Balance as of period end |
| 2020-06-30 | $1.38B | +18.5% | 2021-08-25, Balance as of period end |
| 2019-06-30 | $1.17B | +8.0% | 2020-08-26, Balance as of period end |
| 2018-06-30 | $1.08B | +13.6% | 2020-08-26, Balance as of period end |
| 2017-06-30 | $949.63M | +8.0% | 2019-11-06, Balance as of period end |
| 2016-06-30 | $879.28M | +3.8% | 2018-08-27, Balance as of period end |
| 2015-06-30 | $846.93M | +6.5% | 2017-09-07, Balance as of period end |
| 2014-06-30 | $795.26M | +7.8% | 2016-08-29, Balance as of period end |
| 2013-06-30 | $737.54M | +9.4% | 2015-08-31, Balance as of period end |
| 2012-06-30 | $674.44M | +15.1% | 2014-08-29, Balance as of period end |
| 2011-06-30 | $586.12M | +16.8% | 2013-08-29, Balance as of period end |
| 2010-06-30 | $501.79M | +9.9% | 2012-08-29, Balance as of period end |
| 2009-06-30 | $456.48M | n/a | 2011-08-29, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.11B | +9.9% |
| Novavax Inc (NVAX) | 2025-12-31 | -$127.75M | n/m |
| Halozyme Therapeutics, Inc. (HALO) | 2025-12-31 | $48.81M | -86.6% |
| BioCryst Pharmaceuticals Inc (BCRX) | 2025-12-31 | -$119.15M | n/m |
| Moderna, Inc. (MRNA) | 2025-12-31 | $8.65B | -20.6% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.11B | +6.8% |
| Qiagen N.V. (QGEN) | 2025-12-31 | $3.78B | +5.9% |
| Exelixis, Inc. (EXEL) | 2026-01-02 | $2.16B | -3.7% |
| Neurocrine Biosciences Inc (NBIX) | 2025-12-31 | $3.25B | +25.6% |
Compare TECH, NVAX, HALO, BCRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗